Edaravone/(+)-2-Decanol

依达拉奉/右旋莰醇

Report date: 2026/04/07 20:00:20
NME

Base Information

Drug NameEdaravone/(+)-2-Decanol
Drug Alias Nameedaravone/borneol依达拉奉/右旋龙脑edaravone + 2-borneol依达拉奉/冰片Edaravone/(+)-2-decanol +[20] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFree radicals scavengersTumor necrosis factor α inhibitorsInterleukin-1 beta inhibitors +[5] 
TargetsFree radicalsTumor necrosis factor αInterleukin-1 beta +[5] 
Therapy Area/IndicationsIschemic StrokeCognition DisordersAmyotrophic Lateral Sclerosis +[7] 
Global Approved IndicationsStroke
Approved Indications in ChinaStroke
Original Approved Country/TerritoryMainland China
Original Approved Date2020/07/29
Country/TerritoryUnited StatesMainland China
CombinationsYes (+)-2-DecanolEdaravone
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Simcere Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSimcere Pharmaceutical Co LtdNeuroDawn Pharmaceutical Co LtdJiangsu Simcere Pharmaceutical Co Ltd +[8] 
Inactive CompaniesJiangsu Xiansheng Medicament Research Co Ltd
Active IndicationsIschemic StrokeCognition DisordersAmyotrophic Lateral Sclerosis +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN07XX14
Related LinksN/A